Paul Rugman

2.8k citations

21 papers · 776 indexed · h-index 10

Physiology top 5%
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%
Emergency Medical Services top 2%
Molecular Biology

Co-authors: Mona Bafadhel Christopher E. Brightling Dhananjay Desai Richard May Joanne Woods Paul Newbold Margaret McCormick Salman Siddiqui
Topics: Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers)Asthma and respiratory diseases (8 papers)Respiratory and Cough-Related Research (4 papers)
Cited by: Emergency Medical Services Physiology Immunology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaCHEST Journal
Partner nations: United Kingdom United States Spain

In The Last Decade

Paul Rugman

21 papers receiving 766 citations

Peers

Countries citing papers authored by Paul Rugman

Since Specialization

Citations

This map shows the geographic impact of Paul Rugman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Rugman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Rugman more than expected).

Fields of papers citing papers by Paul Rugman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Rugman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Rugman. The network helps show where Paul Rugman may publish in the future.

Co-authorship network of co-authors of Paul Rugman

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Rugman. A scholar is included among the top collaborators of Paul Rugman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Rugman. Paul Rugman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329) 2022 ·Gynecologic Oncology ·(unknown),Jae‐Weon Kim,Rutie Yin,Fabian Trillsch,Alexander Reuß,Carol Aghajanian,María Jesús Rubio-Pérez,Mehmet Ali Vardar,Giovanni Scambia,Anne Floquet,Gitte‐Bettina Nyvang,Nicoletta Colombo,Mariusz Bidziński,Christian Marth,Stéphanie Lheureux,Els Van Nieuwenhuysen,Paul Rugman,(unknown),Philipp Harter	4
2	DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. 2019 ·Journal of Clinical Oncology ·Philipp Harter,Mariusz Bidziński,Nicoletta Colombo,Anne Floquet,M.J. Rubio Pérez,Jae‐Weon Kim,Stéphanie Lheureux,Christian Marth,Gitte‐Bettina Nyvang,Aikou Okamoto,Alexander Reuß,Giovanni Scambia,Fabian Trillsch,Mehmet Ali Vardar,Els Van Nieuwenhuysen,(unknown),Paul Rugman,Philip Twumasi‐Ankrah,Carol Aghajanian	33
3	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup 2019 ·Allergy ·Sarah Diver,Matt Richardson,Koirobi Haldar,Michael A. Ghebre,Mohammadali Yavari Ramsheh,Mona Bafadhel,Dhananjay Desai,(unknown),Paul Newbold,Laura Rapley,Paul Rugman,Ian Pavord,Richard May,Michael R. Barer,Christopher E. Brightling	32
4	Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma 2018 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Paul Rugman,(unknown),Stefan Ivanov,Mohib Uddin	1
5	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles 2018 ·Journal of Allergy and Clinical Immunology ·Michael A. Ghebre,(unknown),Sarah Diver,Dhananjay Desai,Mona Bafadhel,Koirobi Haldar,Tatiana Kebadze,E. Suzanne Cohen,Paul Newbold,Laura Rapley,Joanne Woods,Paul Rugman,Ian Pavord,Sebastian L. Johnston,Michael R. Barer,Richard May,Christopher E. Brightling	114
6	Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma 2018 ·Drug Design Development and Therapy ·Eric D. Bateman,(unknown),Paul Rugman,(unknown),Stefan Ivanov,Mohib Uddin	22
7	A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK 2018 ·Cancer Chemotherapy and Pharmacology ·Emma Dean,Udai Banerji,Jan H.M. Schellens,Matthew Krebs,Begoña Jiménez,Emilie M.J. van Brummelen,C. C. Bailey,(unknown),(unknown),Marie Cullberg,Stephen O. Evans,Andrew Foxley,Justin P.O. Lindemann,Paul Rugman,Nigel A. S. Taylor,(unknown),James Yates,Peter Lawrence	18
8	Overlapping biologic exacerbation clusters in asthma and chronic obstructive pulmonary disease have distinct sputum mediator and microbiome profiles 2018 ·Michael A. Ghebre,(unknown),Sarah Diver,Dhananjay Desai,Mona Bafadhel,Koirobi Haldar,Tatiana Kebadze,(unknown),Paul Newbold,Laura Rapley,Joanne Woods,Paul Rugman,Ian Pavord,Sebastian L. Johnston,Michael R. Barer,Richard May,Christopher E. Brightling	2
9	BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population 2017 ·Annals of Oncology ·Nicholas C. Turner,(unknown),Anne Armstrong,(unknown),Yamil Alonso Lopez Chuken,(unknown),Kenji Tamura,(unknown),José Alejandro Pérez Fidalgo,Andrew Foxley,Justin P.O. Lindemann,Rhiannon Maudsley,(unknown),Martin Pass,Paul Rugman,Gaia Schiavon,Mafalda Oliveira	1
10	Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer 2017 ·Annals of Oncology ·(unknown),Jennifer K. Litton,Rhys Williams,Pamela T. Soliman,Michael Frumovitz,Kathleen M. Schmeler,Amir A. Jazaeri,Anil K. Sood,Karen H. Lu,Stacy L. Moulder,Rashmi K. Murthy,Maria Alma Rodriguez,(unknown),(unknown),(unknown),Paul Rugman,Justin P.O. Lindemann,(unknown),Gordon B. Mills,Robert L. Coleman	12
11	A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. 2015 ·Journal of Clinical Oncology ·Udai Banerji,Emma Dean,José Alejandro Pérez Fidalgo,Gerald Batist,Philippe L. Bédard,Benoît You,Shannon N. Westin,Peter Kabos,Barry R. Davies,Paul Elvin,Peter Lawrence,James Yates,Helen Ambrose,Paul Rugman,Andrew Foxley,(unknown),(unknown),Justin P.O. Lindemann,Jan H.M. Schellens	5
12	Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies. 2015 ·Journal of Clinical Oncology ·Emma Dean,Udai Banerji,Jan H.M. Schellens,Matthew Krebs,Begoña Jiménez,Ruud van der Noll,Andrew Foxley,James Yates,Nigel A. S. Taylor,Stephen O. Evans,(unknown),(unknown),Paul Rugman,(unknown),Justin P.O. Lindemann,Peter J. Lawrence	1
13	Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease 2014 ·Journal of Allergy and Clinical Immunology ·Michael A. Ghebre,Mona Bafadhel,Dhananjay Desai,E. Suzanne Cohen,Paul Newbold,Laura Rapley,(unknown),Paul Rugman,Ian Pavord,Chris Newby,Paul R. Burton,Richard May,Christopher E. Brightling	95
14	Determinants Of Carotid Intima-Media Thickness In Patients With COPD: The Ciroco Study 2011 ·Lowie E.G.W. Vanfleteren,Frits M.E. Franssen,Martijn A. Spruit,Miriam Groenen,Jos Op ’t Roodt,Paul Rugman,Emiel F.�M. Wouters	1
15	Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD 2010 ·CHEST Journal ·Camille Doe,Mona Bafadhel,Salman Siddiqui,Dhananjay Desai,Vijay Mistry,Paul Rugman,Margaret McCormick,Joanne Woods,Richard May,Matthew A. Sleeman,Ian K. Anderson,Christopher E. Brightling	309
16	Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD 2009 ·Respiration ·Mona Bafadhel,(unknown),Roshan Siva,Michael McCormick,William Monteiro,Paul Rugman,P M Dodson,Ian Pavord,Paul Newbold,Christopher E. Brightling	42
17	The Sensitivity and Specificity of Peripheral Blood Eosinophilia To Predict Sputum Eosinophilia in COPD Subjects. 2009 ·Mona Bafadhel,Sharon L. McKenna,(unknown),Colm J. Reid,Vijay Mistry,Paul Rugman,(unknown),Christopher E. Brightling	2
18	Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD 2009 ·Journal of Clinical Immunology ·Elizabeth Sapey,Ali Ahmad,D Bayley,Paul Newbold,Noel Snell,Paul Rugman,Robert A. Stockley	73
19	Imbalances between Interleukin-1 and Tumour Necrosis Factor Agonists and Antagonists in Stable COPD. 2009 ·Elizabeth Sapey,Ali Ahmad,D Bayley,Paul Newbold,Noel Snell,Paul Rugman,(unknown)	2
20	The 18th Meeting of the British Inflammation Research Association held at the University of Southampton on 14–15 April, 1994 1995 ·Inflammation Research ·Andrew Hutchings,Paul Rugman,(unknown)	6

About Paul Rugman

Paul Rugman is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services, having authored 21 papers that have together received 776 indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers), Asthma and respiratory diseases (8 papers) and Respiratory and Cough-Related Research (4 papers). The work is most often cited by research in Emergency Medical Services (181 citations), Physiology (470 citations) and Immunology (271 citations). Paul Rugman has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Mona Bafadhel, Christopher E. Brightling, Dhananjay Desai, Richard May, Joanne Woods, Paul Newbold, Margaret McCormick, Salman Siddiqui, Vijay Mistry and Camille Doe. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact